Allos Therapeutics (ALTH)

Currency in USD
1.820
0.000(0.00%)
Closed·
Showing Allos Therapeutics historical data. For real-time data please try another search
Day's Range
1.8101.820
52 wk Range
0.0001.820
Key Statistics
Prev. Close
1.82
Open
1.81
Day's Range
1.81-1.82
52 wk Range
0-0
Volume
-
Average Volume (3m)
432.85K
1-Year Change
-1.09%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Allos Therapeutics Company Profile

Allos Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of anti-cancer therapeutics. It focuses on the development and commercialization of FOLOTYN (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is approved in the United States for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is also developing FOLOTYN in other hematologic malignancies. The company has a strategic collaboration agreement with Mundipharma International Corporation Limited (Mundipharma) to co-develop FOLOTYN. Allos Therapeutics, Inc. has commercialization rights for FOLOTYN in the United States and Canada; and Mundipharma has rights to commercialize FOLOTYN in other countries. Allos Therapeutics, Inc. and Mundipharma are seeking regulatory approval to market FOLOTYN in the European Union and other geographies for the treatment of patients with relapsed or refractory PTCL; and are developing FOLOTYN in other potential indications. The company was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in October 1994. Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. As of September 4, 2012, Allos Therapeutics, Inc. operates as a subsidiary of Spectrum Pharmaceuticals, Inc.

Earnings

Latest Release
Mar 06, 2019
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ALTH Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.